Drug intelligence / Profile preview

melatonin (Alturix)

Development stage
Unknown
Lead developer
Kelso Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

Ceyesto is a brand of melatonin, a naturally occurring hormone produced by the pineal gland that regulates the sleep-wake cycle (circadian rhythm). Developed by ALTURiX, Ceyesto is available as an immediate-release 3 mg tablet and a 1 mg/ml oral solution. It is indicated for the short-term treatment of jet lag in adults, and for the treatment of insomnia in children and adolescents aged 6 to 17 years with Attention Deficit Hyperactivity Disorder (ADHD) where sleep hygiene measures have been insufficient. The oral solution is also indicated for delayed sleep-wake phase disorder (DSWPD) in individuals aged 6 to 25 years, and for short-term sedation to facilitate electroencephalograms (EEGs) in children and adolescents aged 1 to 18 years. Melatonin acts as an agonist at melatonin receptors MT1 and MT2 in the brain to promote sleep.

Brand names
AdaflexCeyestoCircadinMellozzanSlenytoSyncrodin
Other names
melatonin
02

Targets

NQO2 (Ribosyldihydronicotinamide dehydrogenase [quinone])MTNR1A (MT1)MTNR1B (Melatonin Receptor 2)

Beyond the preview

Go deeper on melatonin (Alturix).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on melatonin (Alturix).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call